Critical dissolution tests of oral systems based on statistically designed experiments. III. In vitro/in vivo correlation for multiple-unit capsules of paracetamol based on PLS modeling

Drug Development and Industrial Pharmacy

Volumn 24, Issue 4, 1998, Pages 371-383

  Abuzarur Aloul, R ^a   Gjellan, K ^a   Sjolund M ^a   Graffner, C ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ALCOHOL; BILE SALT; ETHYL CELLULOSE; GELATIN; GLUCOSE; HYDROCHLORIC ACID; PARACETAMOL; POVIDONE; SODIUM CHLORIDE; TAUROCHOLIC ACID;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DESIGN; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; EFFERVESCENT TABLET; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; OSMOLALITY; PARTITION COEFFICIENT; PH; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SINGLE BLIND PROCEDURE; STATISTICAL ANALYSIS; STATISTICAL MODEL; VISCOSITY;

EID: 0031923288     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.3109/03639049809085633     Document Type: Article

References (31)

1. H. Quiding, C. Ström, S. Engevall, O, Forsberg, and O. Larsson, Abstract of papers for American Society, Clin. Pharmacol. Ther., 45, 175 (1989).
2. J. C. Nielsen, P. Bjerring, L. Arendt-Nielsen, and K. J. Pettersson, Analgesic efficacy of immediate and sustained release paracetamol and plasma concentration of paracetamol. Double blind, placebo-controlled evaluation using painful laser stimulation, Eur. J. Clin. Pharmacol., 42, 261-264 (1992).
3. M. Hossain and J. W. Ayres, Pharmacokinetics and pharmacodynamics in the design of controlled release beads with acetaminophen as model drug, J. Pharm. Sci., 81, 5, 444-448 (1992).
4. M. Ahmed and R. P. Enever, Formulation and evaluation of sustained release paracetamol tablets, J. Clin. Hosp. Pharm., 6, 27-38 (1981).
5. M. Eandi, I. Viano, and S. Ricci Gamalero, Absolute bioavailability of paracetamol after oral and rectal administration in healthy volunteers, Drug. Res., 34(II), 8, 903-907 (1984).
6. B. Ameer, M. Divoll, D. R. Abernethy, D. J. Greenblatt, and L. Shargel, Absolute and relative bioavailability of oral acetaminophen preparations, J. Pharm. Sci., 77, 8, 995-958 (1983).
7. M. D. Rawlins, D. B. Henderson, and A. R. Hajib, Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration, Eur. J. Clin. Pharmacol., 11, 283-286 (1977).
8. C. Graffner, H. Arwidsson, and H. Quiding, in Proceedings of the 16th International Symposium on Controlled Release of Bioactive Materials, (R. Pearlman and J. Allen Miller, eds.), CRS Inc., Chicago, 1989.
9. C. Graffner, M. Särkelä, K. Gjellan, and G. Nork, Use of statistical experimental design in the further development of a discriminating in vitro release test for ethyl cellulose ER-coated spheres of remoxipride, Eur. J. Pharm. Sci., 4, 73-83 (1996)
10. R. Abuzarur-Aloul, K. Gjellan, M. Sjölund, M. Löfqvist, and C. Graffner, Critical dissolution tests of oral systems based on statistically designed experiments. I. Screening of critical fluids and in vitro/in vivo modelling of extended release coated spheres, Drug. Dev. Ind. Pharm., 23(8), 749-760 (1997).
11. R. Abuzarur-Aloul, K. Gjellan, M. Sjölund, and C. Graffner, Critical dissolution tests of oral systems based on statistically designed experiments. II. In vitro optimization of screened variables on ER-coated spheres for the establishment of an in vitro/in vivo correlation., Drug Dev. Ind. Pharm., 24(3), 1-10 (1998).
12. F. Langenbucher, Linearization of dissolution rate curves by the Weibull distribution, J. Pharm. Pharmacol., 24, 979-981 (1972).
13. F. Langenbucher, Parametric representation of dissolution-rate curves by the RRSBW distribution, J. Pharm. Ind., 38(5), 472 (1976).
14. United States Pharmacopeia, 23rd ed., The United States Pharmacopeial Convention, Inc., Rockville, MD, 1995.
15. G. E. P. Box, W. G. Hunter, and J. S. Hunter, Statistics for Experimenters, Wiley, New York, 1978.
16. W. J. Weibull, Appl. Mech., 18, 293 (1951).
17. A. Höskuldsson, PLS-regression methods, J. Chemom., 2, 211-228 (1988).
18. F. Langenbucher, Numerical convolution/deconvolution as a tool for correlating in vitro with in vivo drug availability, Pharm. Ind., 44, 1166-1172 (1982).
19. M. E. Aulton, Pharmaceutics: The Science of Dosage Form Design, Churchill Livingstone, Edinburgh, UK, 1992, p. 155
20. J. A. H. Forrest, J. A. Clements, and L. F. Prescott, Clinical pharmacokinetics of paracetamol, Clin. Pharmacokin., 7, 93-107 (1982).
21. J. M. Jaffe, J. L. Cloazzi, and H. Barry, Effects of dietary components of GI-absorption of acetaminophen tablets in man, J. Pharm. Sci., 60, 1646-1650 (1971).
22. J. C. Wessels, H. A. Koeleman, B. Boneschans, and H. S. Steyn, The influence of different types of breakfast on the absorption of paracetamol among members of an ethnic group, Int. J. Clin. Pharmacol. Ther. Toxicol., 30, 6, 208-213 (1992).
23. I. J. MacGilveray and G. L. Mattok, Some factors affecting the absorption of paracetamol, J. Pharm. Pharmacol., 24, 615-619 (1972).
24. T. Ueno, A. Tanaka, Y. Hamanaka, and T. Suzuki, Serum drug concentrations after oral administration of paracetamol to patients with surgical resection of the gastrointestinal tract, Br. J. Clin. Pharmacol., 39, 330-332 (1995).
25. N. Katori, N. Aoyagi, and T. Terao, Estimation of agitation intensity in the GI tract in humans and dogs based on in vitro/in vivo correlation, Pharm. Res., 12, 2 (1995).
26. H. A. Lieberman and L. Lachman, Pharmaceutical Dosage Forms. Tablets, Volume 2, Marcel Dekker, 1981, p. 271.
27. T. T. Karali, Comparison of the gastrointestinal anatomy, physiology and biochemistry of humans and commonly used laboratory animals, Biopharm. Drug Dispos., 16, 351-380 (1995).
28. P. R. Holt, Fats and bile salts. I. Physiologic considerations, J. Am. Diet. Assoc. 60(6), 491-495 (1972).
29. J. E. Polli, J. R. Crison, and G. L. Amidon, Novel approach to the analysis of in vitro-in vivo relationships, J. Pharm. Sci. 85(7), 753-760 (1996).
30. G. L. Amidon, H. Lennernäs, V. P. Shah, and J. R. Crison, A theoretical basis for a biopharmaceutical drug classification. The correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm. Res. 12(3), 413-419 (1995).
31. Anne-Sophie Ohlberger, Pharmaceutical R&D, Astra Läkemedel AB, SE-151-85 Södertälje, Sweden, personal communication.